Ispire Technology Inc. ISPR 深 滬
已收盤 08-08 16:00:00 美东时间
2.45
-0.040
-1.61%
華盛通- 最 高2.56
- 今 開2.48
- 成交量 8.81万股
- 最 低 2.43
- 昨 收 2.49
- 總市值 1.40亿
- 52周最高 7.79
- 市盈率 靜 --
- 換手率 0.15%
- 52周最低 2.09
- 委 比 89.53%
- 總股本 5714.55万
- 歷史最高 19.78
- 量 比 2.90
- 振 幅 5.22%
- 歷史最低 2.09
- 每 手 1
- 風險率 2.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多M&M's maker Mars taps CRISPR tech to improve cocoa production
Mars, maker of M&M's and Skittles, is turning to CRISPR gene editing to develop more resilient cacao plants, with the aim of strengthening cocoa production by tackling agricultural challenges. The ca...
08-07 16:38
Crispr director George buys $51.5M of shares
Crispr Therapeutics (NASDAQ:CRSP) has disclosed a $51.5 million stock purchase by board director Simeon George in an SEC filing. Crispr surged as much as 21% on Friday, marking its biggest intraday ga...
07-18 22:08
CRISPR Stock Surges in Recent Weeks: What's Going On?
CRISPR Therapeutics AG (NASDAQ:CRSP) is trending Thursday, up more than 45% ove...
07-11 01:22
Vertex's CASGEVY Shows Over 5.5 Years Of Durable Benefit In Sickle Cell And Beta Thalassemia Trials Presented At The EHA Congress; Multiple Reimbursement Agreements Secured
- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY® -- Multiple reimbursement agreements secured, expanding access to CASGEVY
07-03 21:41
CRISPR delays early-stage readout for heart disease therapy
CRISPR Therapeutics (NASDAQ:CRSP) has delayed a much-anticipated Phase 1 trial readout for CTX320, its in vivo gene editing therapy targeting lipoprotein((a)) [Lp((a))], a risk factor associated with ...
06-26 20:42
礼来(LLY.US)收购Verve(VERV.US)带来行业提振 基因编辑板块迎上涨
专注于基因疗法的生物科技公司股价上涨，原因是礼来(LLY.US)同意以总计不超过 13 亿美元的价格收购位于波士顿的基因编辑初创企业Verve Therape...
06-18 11:28
Lilly-Verve deal sends gene editing stocks higher
Biotech firms focused on gene therapies traded higher after Eli Lilly (NYSE:LLY) agreed to acquire Boston-based gene-editing startup Verve Therapeutics (NASDAQ:VERV) for a total consideration of up to...
06-17 22:29
Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition
Eli Lilly is acquiring Verve Therapeutics to strengthen its cardiovascular pipeline with a gene-editing drug targeting PCSK9-linked conditions.
06-17 20:07
礼来拟13亿美元收购Verve Therapeutics
（转自：药研网） 据外媒6月17日报道，礼来（Eli Lilly）正就收购基因编辑初创公司Verve Therapeutics（纳斯达克代码：VERV）展开深入...
06-17 09:43
